HLDF-6-H Peptide Exhibits an Anti-inflammatory Effect in the Development of Depression in an MPTP Model of Parkinson's Disease

In this work, we investigate the anti-inflammatory effect of the HLDF-6-H peptide (Thr-Gly-Glu-HseHis-Arg) in a model of the presymptomatic stage of Parkinson’s disease (PD). This peptide is a bioactive fragment of the HLDF leukocyte differentiation factor. The presymptomatic stage of PD was modelled by introducing moderate doses of MPTP toxin to C57Bl/6 mice. HLDF-6-H was administered intranasally at a dose of 300 μg/kg daily for three weeks. The severity of depression was determined by the time of immobilization in a Porsolt test. The serum levels of 10 steroids were determined using MS analysis. The activity of inflammatory markers leukocyte elastase (LE) and α1-proteinase inhibitor (α1-PI) was determined using kinetic methods. The development of an inflammatory process under the influence of MPTP is evidenced by an increase in the activity of α1-PI; the anti-inflammatory effect of the peptide is manifested in a decreased activity of LE and α1-PI. At the same time, the immobilization time of mice in a Porsolt test positively correlated with α1-PI and LE, which may indicate the role of inflammation in the development of depression. A positive correlation between estradiol and LE was found in the general sample of mice. In the group of mice treated with the peptide, α1-PI correlated positively with corticosterone and negatively with estradiol and androstenedione. It can be assumed that the anti-inflammatory effect of the peptide is associated with the regulation of corticosteroids and sex hormones. Hence, the applied experimental model confirmed the development of a depressive-like syndrome and neuroendocrine disorders in the presymptomatic stage of PD. The long-term use of HLDF-6-H has antidepressant and anti-inflammatory effects.

1. Androsova L.V., Vetlugi-na T.P., Nikitina V.B., Zozulya S.A., Otman I.N., Belokrylova M.F., Klyushnik T.P. Vospalitel'nye markery priorganicheskih nepsihoticheskih rasstrojstvah [Inflammatory markers in organic nonpsychotic disorders]. S.S. Korsakov J. of Neurology and Psychiatry. 2023;123(3):88–93. (In Russian)]. DOI: 10.17116/jnevro202312303188.

2. Zozulya S.A., Tikhonov D.V., Kaleda V.G., Klyushnik T.P. Immunovospalitel'nye markery stanovleniya remissii posle pervogo psihoticheskogo pristupa v yunosheskom vozraste. [Immunoinflammatory markers of remission formation after the first psychotic attack in adolescence]. S.S. Korsakov J. of Neurology and Psychiatry. 2021;121(6):59–66. (In Russian)]. DOI: 10.17116/jnevro202112106159.

3. Sokolov O.Yu., Prokhorova T.A., Tereshkina E.B., Zozulya S.A., Simonov A.N., Kost N.V., Dadayan A.K., Bogachouk A.P., Zolotarev Yu.A. Neurotropic peptide HLDF-6-amide reduces age-related decline in sexual activity in old male rats. Experimental Gerontology. 149,2021;111329. DOI: 10.1016/j.exger.2021.111329.

4. Zolotarev Yu.A., Shram S.I., Dadayan A.K., Dolotov O.V., Markov D.D., Nagaev I.Yu., Kudrin V.S., Narkevich V.B., Sokolov O.Yu., Kost N.V. HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease. Neuropeptides. 2022;96:10228715. DOI: 10.1016/j.npep.2022.102287.